Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
First Nations and Inuit Health Branch (FNIHB) Pediatric Clinical Practice Guidelines for Nurses in Primary Care
The content of this chapter has been reviewed July 2009
For more information on the history and physical examination of the skin in older children and adolescents, see the chapter, "Skin" in the adult clinical guidelines.
The following characteristics of each symptom should be elicited and explored:
In addition to the general characteristics outlined above, additional characteristics of specific symptoms should be elicited, as follows.
Skin Lesions Up to 1 cm in Greatest Dimension
A: Macule, a flat, circumscribed area of discolouration of the skin or mucous membrane up to 1 cm in its greatest dimension.

B: Papule, a solid, elevated lesion of the skin or mucous membrane up to 1 cm in its greatest dimension.

C: Vesicle, a fluid-filled, superficial, elevated lesion of the skin or mucous membrane, up to 1 cm in its greatest dimension.

Lesions of the skin and mucous membranes are recognized by:
For more descriptions also see Table 1, "Major Types of Skin Lesions" in the chapter, "Skin" in the adult clinical practice guidelines.
Skin Lesions Greater than 1 cm in at Least One Dimension
A: Patch, a flat, circumscribed area of discolouration of the skin or mucous membrane, with at least one dimension greater than 1 cm.

B: Plaque, a solid, elevated lesion of the skin or mucous membrane, with at least one dimension greater than 1 cm.

C: Nodule, a solid, elevated lesion of the skin or mucous membrane, with the added dimension of depth into the underlying tissue, with at least one dimension greater than 1 cm.

D: Tumour, a solid, elevated lesion of the skin or mucous membrane, with the added dimension of depth into the underlying tissue (to a greater extent than for a nodule), with at least one dimension greater than 1 cm.

E: Bulla, a fluid-filled, superficial, elevated lesion of the skin or mucous membrane, with at least one dimension greater than 1 cm.

Wheal, an irregularly shaped, elevated, solid, changing, transient lesion of the skin or mucous membrane, due to cutaneous edema. Other lesions of variable size include pustules (vesicle or bulla containing pus rather than clear fluid) and telangiectasias (fine, often irregular red lines produced by dilatation of a capillary).

Chronic inflammatory disease of the skin with an eruption of papules or pustules. Most common skin disorder in adolescents and seen to some degree in all adolescents.
Non-inflammatory lesions, such as open and closed comedones, are precursors to inflammatory lesions.
Although not life-threatening, acne may have serious psychological effects on self-conscious adolescents.
Acne involves the sebaceous follicles, which are sebaceous glands emptying into hair follicles. Found mainly on the face, chest and back, these follicles are stimulated at puberty by increasing levels of androgen. The follicles produce greater amounts of sebum (oil), which combines with keratin from the lining of the follicle to form plugs (comedones). Bacteria (specifically Propionibacterium acnes) invade the comedones and produce lipases, which break down the sebum into free fatty acids. These compounds cause inflammation and subsequent rupture of the follicle.
Comedones
Papules
Pustules
Nodules and Cysts
| Mild (localized, inflammatory) | Moderate (widespread, resistant, inflammatory) | Severe (scarring, inflammatory) |
|---|---|---|
| Comedones | Comedones | |
| Papules | Many papules | |
| Few pustules | Many pustules | Nodulocystic |
| Scars may be present | Scars on face/chest and back |
Consult a physician if there is failure to respond to the therapies recommended in Table 2, "Acne Treatments According to Severity" or if the person has moderate to severe inflammatory disease. Retinoids, topical antibiotics or isotretinoin may be required.
Client Education
Interventions depend on the severity of acne. See Table 1, "Determining Acne Severity" and then base treatment according to severity. (provide link to Table 1, above)
| Mild (localized, inflammatory) | Moderate (widespread, resistant, inflammatory) | Severe |
|---|---|---|
| Topical benzoyl peroxide (such as Benzagel) or Topical retinoids such as tretinoin (such as Stieva-A) + if necessary add Topical antibiotics such as clindamycin (for example, Dalacin T solution) |
Topical benzoyl peroxide or Topical antibiotics (for example, Dalacin T solution) or Topical retinoids (for example, Stieva-A) and Oral antibiotics (for example, tetracycline*) +/- Oral contraceptive pills (for example, Alesse) (women only) or Oral retinoids for acne scarring (isotretinoin [Accutane]) |
Oral antibiotics (for example, tetracycline*) +/- Oral contraceptive pills (for example, Alesse) (women only) or Antiandrogen (for example, spironolactone) or Oral retinoids for acne scarring (isotretinoin [Accutane]) |
*Note: Never give tetracycline to children 8 years of age and younger or to a pregnant woman.
See the adolescent every 2 or 3 weeks at the beginning of treatment to encourage compliance and monitor efficacy of interventions. Consult with a physician as needed.
Referral to a dermatologist may be warranted in severe cases and those unresponsive to recommended treatments.
Acute, diffuse, spreading infection of the skin, involving the deeper layers of the skin and subcutaneous tissue.
Periorbital cellulitis is a special form of cellulitis that usually occurs in children. In this form of cellulitis, unilateral swelling and redness of the eyelid and orbital area as well as fever and malaise are usually present. Be alert for any child who is unable to elevate or move the eyeball and any child with forward displacement of the eyeball, which indicates that the infection has extended into the orbit (orbital cellulitis.)
Facial, periorbital and orbital cellulitis are particularly worrisome, as they can lead to meningitis.
If a bite was the original trauma, different organisms may be involved. See "Skin Wounds of Traumatic Origin" in the chapter, "Skin" in the adult clinical practice guidelines.
Facial cellulitis in children < 3 years old may be due to Hemophilus influenzae or Streptococcus pneumoniae.
Consult physician if any of the following conditions exist:
Do not underestimate cellulitis. It can spread very quickly and may progress rapidly to necrotizing fasciitis. It should be treated aggressively.
Treat on an outpatient basis.
Client Education
If original lesion was caused by trauma, check for tetanus immunization; if not up to date, administer tetanus vaccine.
Oral antibiotics:
cephalexin (Keflex), 25-50 mg/kg/day, divided qid for 10 days (maximum 4 g/day)Footnote 7 ,Footnote 8 ,Footnote 9
For children who are allergic to penicillin:
azithromycin 10 mg/kg/day first day then 5 mg/kg/day PO for remaining four days
Analgesic and antipyretic for pain and temperature control:
acetaminophen (Tylenol), 10-15 mg/kg PO q4-6h prn
Administer IV antibiotics only as directed by a physician:
cefazolin (Ancef), 100 mg/kg/day IV/IM divided q8h
or
ceftriaxone 75 mg/kg/day IV/IM divided q12-24h (maximum 2 g/day)
For children who are allergic to penicillin:
clindamycin 25-40 mg/kg/day IV/IM divided q8h (maximum 3.6 g/day IV)Footnote 9
Antipyretic and analgesic for fever and pain:
acetaminophen (Tylenol), 10-15 mg/kg/dose PO q4-6h prn
Monitor vital signs and affected area frequently for progression.
Inflammation of skin over area covered by diaper; may include erythema, papules, vesicles and occasionally bullae. Ulceration may also be evident.
Contact diaper dermatitis may require mild steroids:
hydrocortisone 0.5% cream (Cortate), applied sparingly tid until rash resolves (5-7 days)
For candidal diaper dermatitis:
clotrimazole cream (Canesten), bid until rash resolves (1-2 weeks)
For severe cases of candidal diaper dermatitis:
clotrimazole cream (Canesten), bid
and
hydrocortisone 0.5% cream (Cortate), applied sparingly tid
Apply topical barrier cream (Zinc oxide) over medicated creams.
Advise follow-up in 1 week if the rash has not improved, or sooner if there are signs that the infection is worsening.
Not usually necessary, unless the condition is recurrent or unresponsive to therapy.
Inflammatory skin disorder characterized by erythema, edema, pruritus, exudate, crusting, pustules and vesicles. It may be an allergic phenomenon.
Eczema is a common problem in children, and those affected are predisposed to impetigo. Eczema can begin in infancy, often becoming quiescent later in childhood. Recurrences and exacerbations are common.
Consult a physician if there is no response to therapy after a 1- to 2-week trial. Higher-potency steroids, if necessary, must be ordered by a physician. Child will likely need a more potent topical steroid or may need a calcineurin inhibitor such as tacrolimus.
Client Education
Wet Lesions
Promote drying and cooling:
normal saline compresses, qid prn
or
aluminum acetate compresses (Burow's solution, diluted 1:20), qid prn
Dry Lesions
Promote lubrication:
Glaxal base or petroleum jelly (Vaseline) bid after bathing and prn
Reduce inflammation if itch is moderate or severe:
hydrocortisone 1% cream (Cortate), bid-tid for 1-2 weeks
Hydrocortisone should be used only sparingly on the face and then only for brief periods.
Gels and creams are used for acute, weeping eruptions. Ointments are used for dry or lichenified lesions. Lotions are used for hairy areas. In general, ointments are less irritating and have better penetration than creams but adherence is lower because they are cosmetically less acceptable.
For itching:
Pruritus associated with eczema is not mediated by histamine so histamine blockade is generally ineffective. Diphenhydramine (Benadryl) given 30-60 minutes prior to bedtime may provide some relief through central sedation.Footnote 10 It should only be given at bedtime.
children 2 to < 12 years: diphenhydramine 1 mg/kg/dose PO hs prn (maximum 50 mg/dose)
children ≥ 12 years: diphenhydramine 50 mg PO hs prnFootnote 11
Use with caution in children < 2 years of age.
Follow up in 1-2 weeks to assess response. Advise parents or caregiver to bring child back to the clinic sooner if there are signs of infection developing.
Arrange elective follow-up with a physician if there is no response to treatment as outlined above.
Vascular nevi, which may be superficial or deep, capillary or cavernous. Often most visible in infancy, tending to diminish in size with age.
For serious cavernous hemangioma, steroids (intralesional or systemic) (for example, prednisone, 1 mg/kg/day) may be useful. However, steroids can be prescribed only by a physician.
Skin lesions occurring in areas exposed to the sun, without other cause. Commonly seen in Aboriginal people throughout North and South America.
Topical steroids may be tried, starting with:
hydrocortisone 0.5% cream (Cortate), bid-tid for 1-2 weeks
More potent topical steroids, such as betamethasone, may be necessary on body parts other than the face. Such drugs must be ordered by a physician.
Refer child to a physician for evaluation if the treatment is unsuccessful.
Highly contagious, superficial bacterial infection of the skin.
Consult a physician if there is no response to therapy.
Client Education
Apply topical antibiotic preparation:
mupirocin cream (Bactroban), tid for 7 to 10 days
Oral antibiotics may be necessary if there are multiple lesions that appear infected:
cephalexin (Keflex), 25-50 mg/kg/day, divided qid for 7 to 10 days (maximum 4 g/day)
For penicillin allergy:
erythromycin 30-40 mg/kg/day, divided q6-8h, PO for 7 to 10 days (maximum 2 g/day)
Topical antibiotics such as mupirocin (Bactroban) may be used alone for small areas or in conjunction with oral antibiotics for larger areas.
Not usually necessary unless complications develop.
Methicillin-resistant Staphylococcus aureus (MRSA) are bacteria that are resistant to partly synthetic penicillins like cloxacillin and methicillin. The bacteria can also be resistant to other antibiotics. It is difficult to treat, as drugs used to treat other strains of Staphylococcus aureus may not be of benefit.Footnote 15 Staphylococcus aureus is normally found on the skin and in the nares of healthy people. Currently, there are two strains of MRSA that have different molecular and antibiotic resistance profiles.Footnote 16
Hospital-Acquired MRSA
Hospital-acquired MRSA happens most often in those who have been in a hospital or health care facility, or had medical procedures done and who have a weakened immune system.Footnote 17
Community-Acquired MRSA (CA-MRSA)
A person is considered to have CA-MRSA if they have not been in the hospital or had a medical procedure done within the past year and they have a positive culture report for MRSA. The infection usually presents on the skin as pimple(s) or boil(s) and is seen in persons that are otherwise healthy.Footnote 17 Currently, the CA-MRSA strains are more likely to be susceptible to antibiotic classes, other than beta-lactams, than hospital-acquired MRSA strains.Footnote 15
Primary care health practitioners must become aware of the emergence of CA-MRSA as a cause of infection in Canada, particularly in First Nations communities.
The prevalence of CA-MRSA in Canada is currently thought to be low but rising in Canadian communities. Children are generally more affected than adults. Most cases are skin infections with principal sites of colonization being the skin, nares and perineum.
For more serious infections chills, fatigue, malaise, headache, muscle aches or shortness of breath may be present.
Obtain a swab for culture and sensitivity in the following situations:
These selected circumstances include the following:
Consult a physician for all cases of suspected or confirmed MRSA infections.
Prevention
The goal of MRSA control is to prevent spread of the bacteria from an infected or colonized individual to other persons.
If skin lesions are present, educate clients in the following:
Role of health care practitioners:
Acute Infection
Mild, localized cutaneous infections such as minor abrasions: wash with antibacterial soap and water.
Superficial, localized infections, such as impetigo folliculitis, furuncles, carbuncles and small abscesses without cellulitis, use:
Acute Infection
Superficial, localized infections, such as impetigo folliculitis, furuncles, carbuncles and small abscesses without cellulitis, one or more of the following measures may be used:
For the immunocompromised host, antimicrobial therapy is recommended in addition to local measures, incision and drainage.
For empiric therapy of mild to moderate, more generalized infections such as cellulitis (where MRSA is not suspected or confirmed) in addition to local measures, choose one of the following antibiotics:
Start with cloxacillin, or first-generation cephalosporin such as cephalexin or Clavulin (amoxicillin/clavulanic acid)
In community known to have MRSA: clindamycin or trimethoprim/sulfamethoxazole (note that trimethoprim/sulfamethoxazole does not provide coverage for Group A beta-hemolytic streptococcus).
Severe or life-threatening staphylococcal infection such as necrotizing fasciitis, necrotizing pneumonia: initial coverage may include vancomycin pending physician consult, culture and sensitivity.
Decolonization
Decolonization refers to the process of eradicating or reducing carriage of a particular organism from the skin, nose or other mucosal surfaces. Consult a physician for guidance in decision to attempt decolonization as success of decolonization is limited.
The available systemic options include rifampin plus another antistaphylococcal antibiotic such as TMP-SMX, clindamycin, fusidic acid, doxycyline or minocycline.
Eradication from the skin can be attempted using topical agents such as chlorhexidine, whereas nasal decolonization usually requires intranasal mupirocin. Eradication from sites other than the nose usually requires systemic and topical therapy in addition to intranasal therapy.
Closely monitor clients being treated for suspected or confirmed minor staphylococcal skin infections to ensure response to treatment. Timing of follow-up depends on type and severity of infection at presentation.
Medevac cases of moderate to severe infections compatible with S. aureus (for example, extensive cellulitis, sepsis, necrotizing fasciitis, necrotizing pneumonia) to hospital for definitive diagnosis and ongoing treatment.
A benign viral condition of the skin. Humans are the only known source of the virus and it is more common in children and adolescents. It is a common cutaneous manifestation of HIV infection. The infection is spread by direct contact, including sexual contact. It is self limiting and usually spontaneously clears in 6-9 months.
Liquid nitrogen cryotherapy may be used to eradicate genital lesions in sexually active adolescents, to prevent spread via sexual contact. Do not use this therapy unless it is ordered by a physician.
Refer child electively to a physician regarding definitive treatment if the parents (or caregiver) are concerned and desire such treatment.
Benign lesions, presenting as bluish black discolouration of the skin. Commonly seen in black, oriental, Inuit and First Nations children. They diminish or disappear during childhood.
These lesions are sometimes confused with bruising and can be inaccurately interpreted as evidence of child abuse.
Pediculosis (head lice) is a common problem in school-aged children.
See "Pediculosis" in the chapter, "Skin" in the adult clinical practice guidelines for detailed information on the clinical presentation and treatment of pediculosis. Treatment of children with pediculosis is the same as for adults.
A type of contact dermatitis, secondary to exposure to poison ivy. Exposure may be indirect, through clothing and pets.
Consult a physician for advice if the rash is severe or widespread.
Client Education
For mild cases:
hydrocortisone 1% cream (Cortate), applied tid to affected area
For moderate to severe cases, discuss a more potent topical steroid with a physician.
For intense pruritus:
Suggest diphenhydramine hydrochloride (Benadryl):
Children 2 to < 6 years: 6.25 mg PO q4-6h prn (maximum 37.5 mg/day)
Children 6 to < 12 years: 12.5-25 mg PO q4-6h prn (maximum 150 mg/day)
Children ≥ 12 years: 25-50 mg PO q4-6h prn (maximum 300 mg/day)Footnote 20
Use with caution in children < 2 years of age due to sedative effects
Occasionally, a tapering course of oral corticosteroids (prednisone) is required (1 mg/kg/day tapering over 14-21 days). Steroids should be given only with a physician order.
Reassess as necessary in 2 or 3 days.
Usually a self-limiting problem.
Superficial fungal infection of skin.
Dermatophytes (fungi) that invade dead tissue, such as the skin's stratum corneum, nails and hair.
The history and physical findings for various forms of tinea are given in Table 3, "History and Physical Findings for Various Forms of Tinea."
| Type | History | Physical Findings |
|---|---|---|
| Tinea pedis | Affects feet Itch severe Scaling and redness, mainly between toes Foul odour may be present Area may be moist, whitened, macerated, cracked Skin peels off easily, with red, tender area underneath One or several small vesicles may be present Vesicles rupture leaving a "collarette" of scales May involve sole of foot with marked scaling (itch minimal) |
Scaling of lateral interdigital areas Moist, whitened, macerated, cracked skin may be present Skin peels off easily with red, raw, tender area underneath One or several small blisters may be present Sole of foot may be involved, with marked scaling Fissures may become secondarily infected (cellulitis ) |
| Tinea cruris | Affects groin Common in men Itch mild to severe Begins as erythema of crural fold Spreads outward May spread onto thighs or buttocks Scrotum and penis usually not affected Often spread by infected towel Often associated with tinea pedis Predisposing factors: excessive sweating, diabetes mellitus, friction |
Involves crural areas and upper inner thigh Scaly reddish brown lesion Sharply defined margin Central clearing absent Groin, thigh, buttock may be involved May be bilateral or unilateral Scrotum and penis usually not affected |
| Tinea corporis | Affects any smooth, nonhairy part of body Scaly, circular or oval skin lesions Frequently itchy May be asymptomatic |
Lesions variable in size Typically a well-circumscribed circular or oval patch Reddish pink and scaly Central clearing Accentuation of redness at outer border Margins scaly, vesicular or pustular |
Secondary bacterial infection (particularly with tinea pedis).
Take skin scrapings (KOH preparation) for mycologic investigation (fungal culture) and direct microscopy.
Consult a physician if the client is under 2 years of age or if there is failure to respond to an adequate trial of antifungal therapy.
Apply compresses (Burow's solution) bid or tid to dry and relieve itch (for tinea pedis and tinea cruris only).
Client Education
For tinea pedis and tinea cruris, topical antifungal agent for at least 2 weeks; continue until 1 week after resolution of lesions:
clotrimazole skin cream (Canesten), bid or tid
For tinea corporis in children under 2 years of age, a physician must be consulted before starting treatment. For children over 2 years of age, apply a topical antifungal agent such as clotrimazole for 4 weeks.
Follow up in 2 weeks to ensure resolution.
Refer to physician if fungal infections are recurrent, if they develop in an immunosuppressed or diabetic client, if there is no response to therapy, or if the nails become involved.
Superficial infection of the scalp by the fungus Microsporum or Trichophyton.
Consult a physician about treatment if you confirm this diagnosis, since topical antifungal agents are ineffective on the scalp. Oral antifungal medication will have to be prescribed.
There is no need to shave the head.
Topical antifungal agents are ineffective on the scalp.
Consult a physician to order:
an antifungal such as terbinafine (Lamisil), which can be obtained on prescription through NIHB from a retail pharmacy
Oral antifungals can have many side effects, including gastrointestinal (GI) disturbances, skin rash, hepatotoxicity and blood dyscrasias, but are generally well tolerated in children.
Follow up every 2 or 3 weeks while the child is receiving medication, to assess adherence, to determine whether there are signs of improvement and to offer support to the parents or caregiver.
It may be necessary to monitor liver function or complete blood count (CBC) depending on which antifungal is chosen. Discuss these tests with a physician.
Infestation of the skin with a mite parasite. Skin eruptions consist variably of wheals, papules, vesicles, burrows and superimposed eczematous dermatitis. The lesions are intensely pruritic, especially at night, which leads to marked excoriation.
In infants, the face, scalp, palms and soles are most commonly involved. In adolescents, the lesions, which often appear as threadlike burrows, occur in the interdigital spaces, groin and genitalia, umbilicus, axillae and on the wrists, elbows, ankles and buttocks.
The Aboriginal population in some areas may be at risk from a number of additional factors, such as:
Consult physician if you are unsure of the diagnosis.
Client Education
Control Measures
Scabicide cream or lotion, applied to entire body, from chin to toes. Emphasize that scabicide must be applied in skin creases, between fingers and toes, between buttocks, under breasts and to external genitalia.
permethrin 5% dermal cream (Nix)
Leave on skin for 8-14 hours. A single application is usually curative, but medication may be re-applied after 1 week if symptoms persist.
The safety of permethrin for infants < 3 months old has not been established. Discuss with physician if the patient is < 3 months old.
Precipitated sulphur (5-10%) in petroleum jelly is a safe alternative therapy for very young infants and pregnant and lactating women. The pharmacist prepares it. It is applied on three consecutive days, left on for 24 hours after application and washed off before the next application. However, data supporting its use are limited.Footnote 23
Pruritus may be a problem, particularly at night. Advise the child and the parents or caregiver that itching may persist for many weeks. To manage itching, suggest:
diphenhydramine hydrochloride (Benadryl):
Children 2 to < 6 years: 6.25 mg PO q4-6h prn (maximum 37.5 mg/day)
Children 6 to < 12 years: 12.5-25 mg PO q4-6h prn (maximum 150 mg/day)
Children ≥ 12 years: 25-50 mg PO q4-6h prn (maximum 300 mg/day)Footnote 20
Use with caution in children < 2 years of age due to sedative effects
If diphenhydramine is too sedating for daytime, a second-generation antihistamine, such as cetirizine (Reactine), can be used during the day with diphenhydramine reserved for bedtime use.Footnote 21
Topical steroids may be useful after scabicide treatment because the rash and itching may persist for several weeks. Nodular lesions may persist for months; on the advice of a physician a mid-potency topical steroid may helpFootnote 21:
betamethasone valerate 0.1% cream (Betaderm), applied bid
Rarely necessary if original diagnosis is correct and adequate eradication treatment is adhered to by the child and his or her contacts.
Local wheal and erythema of skin.
Referral to a dermatological specialist can be considered in consultation with a physician.
Contact physician if any of the following pertain:
If shortness of breath, wheezing or swelling of tongue or mouth occurs, see "Anaphylaxis" in the chapter, "General Emergencies and Major Trauma."
Client Education
Apply topical antipruritic agents:
calamine lotion qid prn
Oral antihistamine to relieve itch and suppress formation of new lesions:
diphenhydramine hydrochloride (Benadryl)Footnote 25
Children 2 to < 6 years: 6.25 mg PO q4-6h prn (maximum 37.5 mg/day)
Children 6 to < 12 years: 12.5-25 mg PO q4-6h prn (maximum 150 mg/day)
Children ≥ 12 years: 25-50 mg PO q4-6h prn (maximum 300 mg/day)
Use with caution in children < 2 years of age due to sedative effects
or a second-generation antihistamine
cetirizine (Reactine)Footnote 26
Children 6 to 12 months: 2.5 mg once daily
Children 12 to 23 months: Initial 2.5 mg once daily; dosage may be increased to 2.5 mg twice daily
Children 2 to 5 years: 2.5 mg/day; may be increased to a maximum of 5 mg/day given either as a single dose or divided into 2 doses
Children 6 years to adult: 5-10 mg/day as a single dose or divided into 2 doses
Refer to a physician for evaluation if lesions are recurrent (to rule out allergies or an underlying organic pathology).
See "Warts" in the chapter, "Skin," in the adult clinical practice guidelines for detailed information on the clinical presentation and treatment of warts. Treatment of warts is the same for children and adults.
Tissue injuries resulting from thermal injury to skin (epidermis) or mucosal surfaces. May include injury to the underlying dermis, subcutaneous tissue, muscle or bone. The extent of injury (the depth of the burn) depends on the intensity of heat (or other exposure) and the duration of exposure.
Burns are common in children and can cause significant morbidity and mortality. They are the leading cause of accidental death in children.
Involves epidermal layer of skin only. Blisters only after 24 hours.
Extends through and destroys dermis. Involves every body system and organ and extends to subcutaneous tissue damaging muscle, bones and interstitial tissue.
This is a form of child abuse that can sometimes be recognized by specific burn patterns. It can be difficult to diagnose. Accurate diagnosis requires a careful history, physical examination and assessment of the child's developmental capabilities, as well as consultation with a physician or admission to hospital for assessment.
Defer history until ABCs (airway, breathing and circulation) have been assessed and stabilized.
| Depth | Cause | Appearance | Sensation | Healing time |
|---|---|---|---|---|
| Superficial (First-Degree) | Ultraviolet exposure Very short flash |
Dry, red Blanches with pressure | Painful | 3 to 6 days |
| Superficial partial-thickness (Second-Degree) | Scald (spill or splash) Short flash |
Blisters Moist, red, weeping Blanches with pressure |
Painful to temperature and air | 7 to 20 days |
| Deep partial-thickness (Second-Degree) | Scald (spill) Flame Oil Grease |
Blisters (easily unroofed) Wet or waxy dry Variable colour (patchy to cheesy white to red) Does not blanch with pressure |
Perceptive of pressure only | > 21 days |
| Full-thickness (Third-Degree) | Scald (immersion) Flame Steam Oil Grease Chemical Electrical |
Waxy white to leathery gray to charred and black Dry and inelastic No blanching with pressure |
Deep pressure only | Never (if > 2 percent total body surface area) |
| Area | % of Child's Body Surface Area, by Age | ||||
|---|---|---|---|---|---|
| Birth to 11 months | 1 year | 5 years | 10 years | 15 years | |
| Head | 19 | 17 | 13 | 11 | 9 |
| Neck | 2 | 2 | 2 | 2 | 2 |
| Trunk | 26 | 26 | 26 | 26 | 26 |
| Buttocks | 5 | 5 | 5 | 5 | 5 |
| Genitals | 1 | 1 | 1 | 1 | 1 |
| Arm | 7 | 7 | 7 | 7 | 7 |
| Hand | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
| Thigh | 5.5 | 6.5 | 8 | 8.5 | 9 |
| Leg | 5 | 5 | 5.5 | 6 | 6.5 |
| Foot | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 |

Child Rule of Nines
For the anterior portion of the body's surfaces, the percentage of body surface area is approximated at 7% for the head, 18% for the trunk, 4.5% for each arm and 8% for each leg. For the posterior portion of the body's surfaces, the percentage of body surface area is approximated at 7% for the head, 18% for the trunk, 4.5% for each arm and 8% for each leg.
Source of illustration: Firefighter Nation WebChief. (2008).
Determining Depth and Percentage of Burn Injuries.

Infant Rule of Nines
For the anterior portion of the body's surfaces, the percentage of body surface area is approximated at 9% for the head, 18% for the trunk, 4.5% for each arm and 7% for each leg. For the posterior portion of the body's surfaces, the percentage of body surface area is approximated at 9% for the head, 13% for the trunk, 2.5% for each buttock, 4.5% for each arm and 7% for each leg.
Source of illustration: Firefighter Nation WebChief. (2008). Determining Depth and Percentage of Burn Injuries.
Table 6: Classification of Burns by Severity (Surface Area Involved)31
Minor
< 5% total body surface area in second-degree burn
< 2% total body surface area in third-degree burn
Moderate
5% to 10% total body surface area in second-degree burn
2% to 5% total body surface area in third-degree burn
High voltage injury
Suspected inhalation injury
Circumferential burn
Medical problem predisposing to infection (for example, diabetes mellitus, sickle cell disease)
Major
> 10% total body surface area in second-degree burn
> 5% total body surface area third-degree burn
Any significant burns on hands, feet, face, eyes, ears, perineum or joints
Any known inhalation injury
High voltage burn
Significant associated head injury, fracture or soft-tissue trauma
Table 7: Classification of Burns by Injury Pattern
Sunburn
Areas exposed to sun
Splash or scald burns
Maximal burns at location of impact, with lesser burns in dependent areas where fluid has cooled and dropped
Multiple small satellite areas of burned skin may occur around scalded areas of skin
Electrical burns
Burns of the mouth and lip, mucosal swelling and coagulation
May have minor entrance and exit wounds, with severe underlying tissue destruction along route of current
Forced immersion burn
Indicative of abuse
Areas of severe burn in immersed areas usually separated from normal skin by sharp demarcation, without splash marks
May be in a stocking distribution or may involve trunk
Spared sharp-edged areas may be present in dependent areas where part of the body is in contact with immersion container
Contact burns
Burned areas bear patterns of specific hot object in contact with the skin (for example, grate, stove element)
May be accidental or intentional
Flame burns
Associated inhalation damage may cause acute respiratory failure
Cigarette burns
Usually discrete circular lesions, well circumscribed
May be a form of child abuse and can be confused with impetigo
Adapted with permission from Ludwig S, Fleisher G. Textbook of pediatric emergency medicine. 2nd ed. Baltimore, MD: Williams and Wilkins; 1988. p. 902-3.
Management is based on the depth of the burns and an accurate estimate of total body surface area (see Table 5, "Assessing Extent of Burns in Children" and Table 6, "Classification of Burns by Severity [Surface Area Involved]").
Consult a physician if there are any concerns about the burn or client (for example, infection, age, pain).
Check whether tetanus immunization is up to date; give tetanus vaccine as needed (refer to the
Canadian Immunization GuideFootnote 35)
First-Degree Burns
Client Education
Analgesia:
ibuprofen (Motrin)
Children 6 months to 12 years of age: ibuprofen 5-10 mg/kg PO q6-8h prn;
Children > 12 years of age: ibuprofen 200-400 mg PO q4-6h prn
Use lowest effective dose, shortest treatment duration; give with food
or
acetaminophen (Tylenol)
Children < 12 years of age: acetaminophen 10-15 mg/kg/dose, PO q4h prn
Children ≥ 12 years of age: acetaminophen 325 mg, 1-2 tabs PO q4h prn (maximum 4 g/day)
Regular dosing may be necessary rather than prn.
Larger, more severe, deep partial-thickness burns require topical antibiotic ointment or impregnated dressings (ointments can make evaluation of drainage difficult). Apply:
Jelonet dressing every other day with an antibiotic ointment
or
framycetin (Sofratulle) dressing, daily
or
silver sulfadiazine (Flamazine), daily
Relative contraindication to silver sulfadiazine: possible cross-sensitivity to other sulfonamides and pregnancy.
Prophylactic antibiotics should rarely be required but may be considered for:
Broad-spectrum coverage with first-generation cephalosporin or with a penicillinase-resistant penicillin plus an aminoglycoside may be used if necessary. Discuss choice with a physician.
Absolute sterility is not mandatory during dressing changes; however, cleanliness and thorough cleansing of hands, sinks, tubs and any instruments used is emphasized.
Consult a physician as soon as the child's condition is stabilized, and prepare to medevac.
Perform Primary Survey
Fluid Resuscitation for Major Burns (see Table 6, "Classification of Burns by Severity")
Table 8: Hourly Maintenance Fluid Requirements (1-hour periods)Footnote 39
Calculation
4 mL/kg/hour for first 10 kg of body weight
+ 2 mL/kg/hour for the next 10 kg of body weight
+ 1 mL/kg/hour for each kilogram over 20 kg of body weight
Maximum of 100 mL/hour or 2400 mL a day needed for maintenance
Examples
For 10 kg child: 10 kg x 4 mL/kg/hour = 40 mL/hour
For 15 kg child: (10 kg x 4 mL/kg/hour) + (5 kg x 2 mL/kg/hour) = 50 mL/hour
For 25 kg child: (10 kg x 4 mL/kg/hour) + (10 kg x 2 mL/kg/hour) + (5 kg x 1 mL/kg/hour) = 65 mL/hour
Burn shock usually takes hours to develop. If shock is evident on initial presentation, look for other causes of volume loss, such as major injury elsewhere in the body. See "Shock" in the chapter, "General Emergencies and Major Trauma."
Special Considerations for Resuscitation
Perform secondary survey and identify associated injuries.
Wound CareFootnote 40
For analgesia, consult a physician first; consider:
morphine in small, frequent doses (0.1 mg/kg/dose), IVFootnote 41
Be alert for respiratory depression with opioids.
There is no indication for prophylactic antibiotics.
Medevac (using criteria in Table 9, "Criteria for Transfer of Burn Patient to Hospital [All Serious Burns]," along with consultation with a physician).
Table 9: Criteria for Transfer of Burn PatientFootnote 42
Thermal injury to tissue caused by cold. Injury may occur without (see Table 10, "Types of Cold Injury Without Frostbite") or with (see Table 11, "Classification of Frostbite") freezing of the tissue. Freezing of the tissue is defined by the formation of ice crystals.
| Type of Injury | Cause | Clinical Observations | Treatment |
|---|---|---|---|
| Chilblain (peripheral cold injury without freezing of tissue) | Prolonged dry exposure at temperatures above freezing | Affected areas are pruritic, reddish blue; may be swollen; may have blisters or superficial ulcerations; areas may be more temperature sensitive in future; no permanent injury | Rewarm as for frostbite (see Nonpharmacologic Interventions); pain medication should be provided |
| Trench foot and immersion injury | Prolonged wet exposure at temperatures above freezing | May have tissue destruction resembling partial-thickness burns, including blisters, pain, hypersensitivity to cold; temperature sensitivity may be permanent | Rewarm as for frostbite (see Nonpharmacologic Interventions) |
| 1st degree injury (frostnip) | 2nd degree injury | 3rd degree injury | 4th degree injury |
|---|---|---|---|
| Gross appearance of the injured area | |||
| Superficial, skin changes reversible White to yellow firm plaque, numb; loss of sensation Comparable to superficial (first-degree) hot thermal burn |
Superficial blisters containing clear or milky fluid with or without erythema and edema in surrounding tissue Blisters appear in 24-48 hours; fluid reabsorbs; hard, blackened eschar may develop; remains sensitive to heat and cold Treat conservatively; generally resolves without surgical intervention in 3-4 weeks |
Deeper blisters containing red or purple fluid, OR darkly discoloured skin without blisters Tissue feels woody under skin; affects muscles, tendons, etc. Hemorrhagic blisters and loss of distal function; may take several months to determine extent of injury Frozen tissue will eventually slough |
Extensive dark and cyanotic skin without blisters or edema |
| Outcome | |||
| Central pale area surrounded by erythema with no tissue lost but pain may be present | Limited superficial skin loss with blisters surrounded by erythema and edema | Hemorrhagic blisters and eschar formation leading to various outcomes depending on depth of injury | Necrosis and tissue lost. Gangrene can occur within a few hours |
Exposure to cold.
Ninety percent of frostbite cases involve the hands and feet, while cheeks, nose, ears and penis are commonly affected.Footnote 45
See also Table 10, "Types of Cold Injury Without Frostbite" and Table 11, "Classification of Frostbite."
Consult a physician for all but first-degree (frostnip) injury.
Check whether tetanus vaccination is up to date; give tetanus vaccine as needed (refer to the most recent
Canadian Immunization Guide).
Prevention Education
Mild Frostbite
Analgesia for pain:
ibuprofen (Motrin), 4-10 mg/kg/dose PO q6-8h prn
or
acetaminophen (Tylenol) 10-15 mg/kg/dose PO q4-6h prn
Moderate to Severe Frostbite
As pain may be severe during rewarming, consult a physician, as morphine may be considered for pain control.
Be alert for respiratory depression if opioids are used.
Mild Frostbite
Reassess and re-dress wound daily for 4-7 days, until the wound is healing well. Monitor for signs of infection.
Medevac anyone with moderate-to-severe frostbite as soon as possible.
Breach in the integrity of the external surface of the body.
Wounds that result from trauma can be categorized by type.
| Wound Type | Definition |
|---|---|
| Laceration | Open wound that results from blunt or sharp trauma to the skin |
| Abrasion | Skin lesion caused by tangential trauma to the dermis and epidermis, similar to a burn |
| Avulsion | Full-thickness tissue loss that prevents the approximation of the edges of the wound. Commonly seen in fingertip, tip of nose, ear lobe or loss of permanent teeth injuries A severe form of avulsion is "degloving" where the full thickness of the skin is peeled away from a finger, hand, foot or an area of limb, causing devascularization of the skin and damage to underlying tissues |
| Puncture wound | Tissue penetration by a blunt or sharp object |
| Foreign body | Any object (for example, wood or metal splinter, body jewellery, glass, fishhook, fragment from gunshot, needles) that becomes embedded in any part of the body. Vegetative foreign bodies (for example, thorns or wood) are highly reactive, lead to infection, and should be removed as soon as possible |
| Missile or velocity wound | Skin lesions caused by an object entering the body at a high speed |
| Bites | Skin lesion self-inflicted (human) or as a result of a person-to-person (human) or animal contact are at increased risk of infection |
Assess for infection:
Assess integrity of underlying structures (nerves, ligaments, tendons, blood vessels):
Consult a physician if any of the following pertain:
Check whether tetanus vaccination is up to date; give tetanus vaccine as needed (refer to the most recent
Canadian Immunization Guide).
Wound Repair: General Principles
Homeostasis
Direct pressure is the first choice for controlling bleeding. If a fracture is involved, immobilization will help control bleeding.
Skin Preparation
Never shave eyebrows. They are needed for alignment of the wound and may not grow back.
Open Wound Care
Wound Closure
| Type of Suture | Size | Body Area | |
|---|---|---|---|
| Nonabsorbable | Nylon-Dermalon, Ethilon | #3-0, 4-0 #5-0, 6-0 #3-0, 4-0, 5-0 #3-0, 4-0, 5-0 #3-0, 4-0, 5-0 |
Scalp Forehead Back Torso Limbs |
| Nylon coated with polypropylene glycol (Prolene) | #5-0, 6-0 | Face | |
| Absorbable | Polygalactin (Vicryl, Dexon) Monofilament (Monocryl) |
#4-0, 5-0 | Subcutaneous tissue Muscle |
Types of Suture Needles
Local Anesthetic for Suturing
Lidocaine 1% is the most frequently used local anesthetic (onset 2-5 minutes, duration 30-60 minutes):
lidocaine (Xylocaine), 1% without epinephrine, 3-4 mg/kg (0.3 to 0.4 mL/kg of a 1% solution without epinephrine; maximum 28 mL). The lowest effective doses should be used in children to avoid systemic toxic effects
Nurses should use 1% lidocaine without epinephrine as the first choice when suturing a wound, as epinephrine prolongs the anesthetic effect and is contraindicated for areas with end arteries or poor circulation (digits, nasal tip, ears, penis). Although rare, an allergic reaction to lidocaine is possible; ensure access to an anaphylaxis kit.
Never use lidocaine with epinephrine on the ears, nose, fingers, toes or penis.47
Antibiotic Prophylaxis
There is no medical indication for prophylactic antibiotics in routine, uncontaminated skin wounds. However, consider prophylactic antibiotic use for clients prone to endocarditis, diabetic clients with a contaminated foot wound or other clients with immunocompromise:
cloxacillin 25-50 mg/kg/day PO divided qid for 7 days (maximum 2g/day)
For clients with allergy to penicillin:
erythromycin 30-40 mg/kg/day PO divided tid or qid for 7 days (maximum 2g/day)
Topical Antibiotics
Consider topical antibiotic ointment for wounds on face and torso:
bacitracin/polymyxin B (Polysporin) ointment, tid or qid for 5 days
Alternatives include the use of antibiotic impregnated dressings such as Sofratulle or silver-coated low-adherent dressing (for example, Acticoat) which act as an antimicrobial barrier.
Antibiotic ointment should not be left on wounds of the distal extremities for more than 24-48 hours, because it may lead to maceration and could delay wound-healing.
Antibiotics for BitesFootnote 48
Human Bites
Antibiotics should be given prophylactically for all human bites:
amoxicillin/clavulanate (Clavulin), 40 mg/kg/day PO divided tid for 3-5 days
Duration of antibiotic use is longer for the treatment of an infection that is already present. Contact a physician to discuss this.
Cefuroxime axetil is a suitable alternative. For those with beta-lactam allergy contact a physician, who may suggest one of the following:
Children ≤ 8 years: clindamycin + TMP/SMX
Children > 8 years: doxycycline
Consider contacting physician for IV antibiotics if infection has already occurred, especially for a bite on the hand.
Cat Bites
Antibiotics are routinely given prophylactically for all cat bites. The drug of choice is:
amoxicillin/clavulanate (Clavulin), 40 mg/kg/day PO divided tid for 3-5 days
Duration of antibiotic use is longer for the treatment of an infection that is already present. Contact a physician to discuss this.
Cefuroxime axetil is a suitable alternative. For those with beta-lactam allergy contact a physician, who may suggest one of the following:
Children ≤ 8 years: clindamycin + TMP/SMX
Children > 8 years: doxycycline
Dog Bites
About 20% of dog bites become infected, and prophylaxis is only recommended under certain circumstances: moderate/severe bites; crush injury/edema; puncture wounds; bone/joint involvement; injuries to hand, foot, face, genitalia; splenectomized patients; immunocompromised.Footnote 48 These should be discussed with a physician. If there is a need to treat, amoxicillin/clavulanate is the drug of choice (as for other types of bites). Consider need for rabies prophylaxis (see "Rabies" in the chapter, "Communicable Diseases" and the most recent
Canadian Immunization Guide for details).
| Wound Location | Removal Time |
|---|---|
| Face | 3-5 days; steri-strip reinforcement after suture removal |
| Scalp | 5-8 days |
| Neck | 3-5 days |
| Chest | 7-10 days |
| Abdomen | 7-10 days |
| Back | 10-12 days |
| Upper extremity Nonjoint surface Joint surface |
7-10 days 10-12 days (consider splinting) |
| Lower extremity Thigh Knee Lower leg Foot |
7-10 days 12-14 days 7-10 days 7-10 days |
Increase time before removal of sutures in diabetic or steroid-dependent clients in whom healing may take several weeks.
Consider referral to a physician:
All internet addresses are valid as of June 2010
Bickley LS. Bates' guide to physical examination and history taking. 7th ed. Baltimore, MD: Lippincott Williams & Wilkins; 1999.
Cheng A, et al. The Hospital for Sick Children handbook of pediatrics. 10th ed. Toronto, ON: Elsevier; 2003.
Cohen J, Powderly WG. Infectious diseases. 2nd ed. New York, NY: Elsevier; 2004.
Colman R, Somogyi R (Editors-in-chief). Toronto Notes - MCCQE 2008 review notes. 24th ed. Toronto, ON: University of Toronto, Faculty of Medicine; 2008.
Ferri FF. Ferri's clinical advisor: Instant diagnosis and treatment. St. Louis, MO: Mosby; 2004.
Fitzpatrick TB, Allen R, Johnson K, et al. Color atlas and synopsis of clinical dermatology. 4th ed. McGraw-Hill; 2001.
Gray J (Editor-in-chief). Therapeutic choices. 5th ed. Ottawa, ON: Canadian Pharmacists Association; 2007.
Habif TP. Clinical dermatology: A color guide to diagnosis and therapy. 4th ed. Baltimore, MD: Mosby; 2004.
Health Canada. Canadian immunization guide. 7th ed. Ottawa, ON: Health Canada; 2006.
Jensen B, Regier L (Editors). The Rx files. 7th ed. Saskatoon, SK: 2008.
McCance KL, Huether SE. Pathophysiology: Biologic basis for disease in adults and children. 4th ed. St. Louis, MO: Mosby; 2002. p. 1527.
Repchinsky C (Editor-in-chief). Compendium of pharmaceuticals and specialties. Ottawa, ON: Canadian Pharmacists Association; 2007.
Rosser W, Pennie R, Pilla N, and the Anti-infective Review Panel (Canadian). Anti-infective guidelines for community-acquired infections. Toronto: MUMS Guidelines Clearing House; 2005.
Rudolph CD, et al. Rudolph's pediatrics. 21st ed. McGraw-Hill; 2003.
Uphold CR, Graham MV. Clinical guidelines in child health. 3rd ed. Gainesville, FL: Barmarrae Books; 2003.
Internet addresses are valid as of April 2010.
Oakley, A. (April 2009) How to treat acne.
Best Practice Journal Issue 20 pages 7-16.
First Nations and Inuit Health Committee, Canadian Paediatric Society (CPS).
Scabies management. Paediatrics & Child Health 2001;6(110):775-7. Reference No. II01-01 (Formerly II94-01). Reaffirmed May 2008.
Barton M, Hawkes M, Moore D, Conly J, et al. The Writing Group of the Expert Panel of Canadian Infectious Disease, Infection Prevention and Control, and Public Health Specialists.
Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners. Can J Infect Dis Med Microbiol 2006;Vol 17 Suppl C.
CunliffeT, Carmichael A. Dermatology guidelines. Produced in collaboration with the Directorate of Dermatology, James Cook University Hospital, London, England; April 2004.
Gibbs S, Harvey I. (2006, May 24).
Topical treatments for cutaneous warts.
Goodis J, Schraga ED.
Thermal burns. Updated: October 29, 2008.
Infectious Diseases and Immunization Committee, Canadian Paediatric Society (CPS).
Community-associated methicillin-resistant Staphylococcus aureus: Implications for the care of children. Paediatrics & Child Health 2007;12(4):323-24.
Koning S, Verhagen AP, van Suijlekom-Smit LWA, Morris A, Butler CC, van der Wouden JC. (2004, April 19).
Interventions for impetigo.
Wolff K, Allen R, Johnson DS. Fitzpatrick's color atlas and synopsis of clinical dermatology. 6th ed. McGraw-Hill; 2009. p. xxvi-xxxiv.
Uphold CR, Graham MV. Clinical guidelines in family practice. 4th ed. Gainesville, FL: Barmarrae Books; 2003. p. 264-69.
Lichtenwald D. Acne. In: Gray J (Editor). Therapeutic choices. 5th ed. Ottawa, ON: Canadian Pharmacists Association; 2007. p. 1013-20.
Filate W, Ng D, Leung R, Sinyor M. Essentials of clinical examination handbook. 5th ed. Toronto, ON: University of Toronto Medical Society; 2005. p. 322.
Wirth FA. (2006, December). Patient Information: Acne.
Wolff K, Allen R, Johnson DS. Fitzpatrick's color atlas and synopsis of clinical dermatology. 6th ed. McGraw-Hill; 2009. p. 617.
Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook. 14th ed. Hudson, OH: Lexi-Comp; 2007.
Lau E (Editor). SickKids drug handbook and formulary.
Rosser WW, Pennie RA, Pilla NJ, and the Anti-infective Review Panel. Anti-infective guidelines for community-acquired infections. Toronto: MUMS Guideline Clearinghouse; 2005.
Weinstein M. Atopic Dermatitis. In: Gray J (Editor). Therapeutic choices. 5th ed. Ottawa, ON: Canadian Pharmacists Association; 2007. p. 1069-76.
Taketomo CK, Hodding JH, Kraus DM. Pediatric dosing handbook. 14th ed. Hudson, OH: Lexi-Comp; 2007. p. 510-11.
Barton M, Hawkes M, Moore D, Conly J, et al. The Writing Group of the Expert Panel of Canadian Infectious Disease, Infection Prevention and Control, and Public Health Specialists. Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners. Can J Infect Dis Med Microbiol 2006;Vol 17 Suppl C.
Canadian Pediatric Society (CPS).
Methicillin-resistant Staphylococcus aureus in First Nations communities in Canada. FNIH 2005-02. Paediatr Child Health 2005;10(9):559.
Dugdale DC, Vyas JM. (2008, September 28).
MRSA. Medline Plus.
Health Link Alberta. (2007, December).
Community Acquired MRSA.
Nicolle L.
Community acquired MRSA: A practitioner's guide. CMAJ 2006;175(2):145-46.
Centers for Disease Control and Prevention. (2009).
Community-Associated Methicillin Resistant Staphylococcus aureus.
Oehler RA, Velez AP, Mizrachi M, Lamarche J, Gompf S. (2009).
Bite-related and septic syndromes caused by cats & dogs. The Lancet Infectious Diseases 2007;9(7):439-47.
Siegel JD, Rhinehart E, Jackson M, Chiarello L & Healthcare Infection Control Practices Advisory Committee. (2006).
Management of multidrug-resistant organisms in healthcare settings.
Taketomo CK, Hodding JH, Kraus DM. Pediatric dosing handbook. 14th edition. Hudson, OH: Lexi-Comp; 2007. p. 510-11.
Goldstein BG, Goldstein AO. (2009, May). Scabies.
First Nations and Inuit Health Committee, Canadian Paediatric Society (CPS).
Scabies management. Paediatrics & Child Health 2001;6(110):775-7. Reference No. II01-01 (Formerly II94-01). Reaffirmed May 2008.
Knowles S, Shear N. Scabies and Pediculosis. In: Gray J (Editor). Therapeutic choices. 5th ed. Ottawa, ON: Canadian Pharmacists Association; 2007. p. 1089-97.
Schilling JA (Executive publisher). Nurse's quick check diseases. 2nd Ed. Wolters Kluwere, Lippincott, Williams & Wilkins; 2009. p. 860-61.
Taketomo CK, Hodding JH, Kraus DM. Pediatric dosing handbook. 14th ed. Hudson, OH: Lexi-Comp; 2007.
Taketomo CK, Hodding JH, Kraus DM. Pediatric dosing handbook. 14th ed. Hudson, OH: Lexi-Comp; 2007.
Labbe J. (2002, July).
Cutaneous signs of physical abuse. The Canadian Journal of CME; 83-92.
Filate W, Ng D, Leung R, Sinyor M (Editors). Essentials of clinical examination handbook. 5th ed. Toronto, ON: University of Toronto Medical Society; 2005.
Adapted from Mertens DM, Jenkins ME, Warden GD. Med Clin North Am 1997;32:343; and Peate WF. Am Fam Physician 1992;45:1321; and Clayton MC, Solem LD. Postgrad Med 1995; 97:151. In: Morgan ED, Miser WF. Treatment of minor thermal burns. May 2009.
McCance KL, Huether SE. Pathophysiology: Biologic basis for disease in adults and children. 4th ed. St. Louis, MO: Mosby; 2002. p. 1527.
Joffe MD. (2009, May). Emergency care of moderate and severe thermal burns in children. UpToDate Online 17.2.
Rice PL. (2009). Emergency care of moderate and severe thermal burns in adults. UpToDate Online 17.2. p. 9.
Hoyt KS, Selfridge-Thomas J (Editors). Emergency nursing core curriculum. 6th ed. Emergency Nurses Association and Saunders-Elsevier; 2007. p. 814.
Joffe MD. (2009, May). Emergency care of moderate and severe thermal burns in children. UpToDate Online 17.2. p. 7.
National Advisory Committee on Immunization (NACI).
Canadian immunization guide. 7th ed. Ottawa, ON: Public Health Agency of Canada; 2006. p. 82.
Joffe MD. (2009, May). Emergency care of moderate and severe thermal burns in children. UpToDate Online 17.2. p. 6.
Joffe MD. (2009, May). Emergency care of moderate and severe thermal burns in children. UpToDate Online 17.2.
Hoyt KS, Selfridge-Thomas J (Editors). Emergency nursing core curriculum. 6th ed. Emergency Nurses Association and Saunders-Elsevier; 2007. p. 812-13.
Somers MJ, Endom EE. (2008, May 30). Maintenance fluid therapy in children. UptoDate Online 16.3.
Joffe MD. (2009, January). Emergency care of moderate and severe thermal burns in children. UptoDate.
Henry DB, Foster RL. Burn pain management in children. Pediatr Clin North Am 2000;47(3):681-98, ix-x.
Hoyt KS, Selfridge-Thomas J (Editors). Emergency nursing core curriculum. 6th ed. Emergency Nurses Association and Saunders-Elsevier; 2007. p. 814. Adapted from Amercian College of Surgeons Committee on Trauma (2004). Advanced Trauma life support for doctors. 7th ed. Chicago: American College of Surgeons.
Table adapted from Hoyt KS, Selfridge-Thomas J (Editors). Emergency nursing core curriculum. 6th ed. Emergency Nurses Association and Saunders-Elsevier; 2007. p. 320.
Table adapted from Robson MC, Smith DJ Jr. Chapter 26: Cold injuries. In: McCarthy JG (Editor). Plastic surgery. WB Saunders Company; 1990. p. 849-66.
Hoyt KS, Selfridge-Thomas J (Editors). Emergency nursing core curriculum. 6th ed. Emergency Nurses Association and Saunders-Elsevier; 2007. p. 320.
Hoyt KS, Selfridge-Thomas J (Editors). Emergency nursing core curriculum. 6th ed. Emergency Nurses Association and Saunders-Elsevier; 2007. p. 742-58.
Hoyt KS, Selfridge-Thomas J (Editors). Emergency nursing core curriculum. 6th ed. Emergency Nurses Association and Saunders-Elsevier; 2007. p. 744.
Blondel-Hill E, Fryters S.
Bugs and drugs 2006. Edmonton (AB): Capital Health; 2006.
Hoyt KS, Selfridge-Thomas J (Editors). Emergency nursing core curriculum. 6th ed. Emergency Nurses Association and Saunders-Elsevier; 2007. p. 745.